Highlights
•Zuranolone (SAGE-217) is an investigational oral neuroactive steroid GABAA receptor positive allosteric modulator (PAM).
•Zuranolone was administered for seven days in 14 patients with PD, and reduction of tremor symptoms was assessed.
•The MDS-UPDRS Part II/III tremor score improved 40% (p < 0.0001) from baseline on Day 8.
•The motor score and non-motor and motor EDL scores (MDS-UPDRS Parts I and II, respectively) also improved at Day 8.
•No serious AEs were reported, and no patients discontinued treatment.Zuranolone